Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
European Heart Journal|March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term studyAlbree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
Circulation. Heart Failure|November 8, 2025
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCMXiaowen Wang, Maria A Pabon, Tracy T Makuvire, et al.
Journal of Cardiac Failure|March 16, 2026
Two Year Results of PROACTIVE-HF Trial Stratified by LVEFJason L Guichard, Eric L Bonno, Michael E Nassif, et al.
Journal of the American College of Cardiology|October 30, 2024
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCMAhmad Masri, Lubna Choudhury, Roberto Barriales-Villa, et al.
Journal of the American College of Cardiology|September 1, 2024
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic CardiomyopathySheila M Hegde, Brian L Claggett, Xiaowen Wang, et al.
JACC. Heart Failure|February 5, 2025
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline CharacteristicsPablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, et al.
JAMA Cardiology|September 4, 2024
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical TrialMatthew M Y Lee, Ahmad Masri, Michael E Nassif, et al.
JACC. Heart Failure|June 20, 2025
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCMSara Saberi, Theodore P Abraham, Lubna Choudhury, et al.
Nature Medicine|October 29, 2021
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trialMichael E Nassif, Sheryl L Windsor, Barry A Borlaug, et al.
JACC. Heart Failure|February 13, 2026
Seated Pulmonary Artery Pressure Management in Patients With Heart Failure: 12-Month Outcomes of the PROACTIVE-HF TrialJason L Guichard, Eric L Bonno, Michael E Nassif, et al.
Pageof 9